Market closed

Protagonist Therapeutics/$PTGX

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Protagonist Therapeutics

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Ticker

$PTGX

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Newark, United States

Employees

126

Website

www.protagonist-inc.com

PTGX Metrics

BasicAdvanced

$2.2B

13.84 $2.68

2.20 -

Price and volume

Market cap

$2.2B

Beta

2.2

52-week high

$47.58

52-week low

$23.17

Average daily volume

639K

Financial strength

Current ratio

10.695

Quick ratio

10.574

Long term debt to equity

2.041

Total debt to equity

2.049

Management effectiveness

Return on assets (TTM)

19.96%

Return on equity (TTM)

40.97%

Valuation

Price to earnings (TTM)

13.841

Price to revenue (TTM)

7.007

Price to book

4.16

Price to tangible book (TTM)

4.16

Price to free cash flow (TTM)

9.898

Growth

Earnings per share change (TTM)

-203.09%

3-year revenue growth (CAGR)

136.78%

3-year earnings per share growth (CAGR)

3.31%

What the Analysts think about PTGX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Protagonist Therapeutics stock.

PTGX Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

PTGX Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

PTGX News

AllArticlesVideos

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Seeking Alpha·2 days ago

Protagonist Therapeutics Reports Granting of Inducement Awards

Accesswire·1 week ago

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

Accesswire·4 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PTGX

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Protagonist Therapeutics stock?

Protagonist Therapeutics (PTGX) has a market cap of $2.2B as of January 15, 2025.

What is the P/E ratio for Protagonist Therapeutics stock?

The price to earnings (P/E) ratio for Protagonist Therapeutics (PTGX) stock is 13.84 as of January 15, 2025.

Does Protagonist Therapeutics stock pay dividends?

No, Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Protagonist Therapeutics dividend payment date?

Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders.

What is the beta indicator for Protagonist Therapeutics?

Protagonist Therapeutics (PTGX) has a beta rating of 2.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.